Keyphrases
Chemotherapy
81%
Colorectal Cancer
73%
Non-small Cell Lung Cancer (NSCLC)
61%
Capecitabine
57%
Tumor
50%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
47%
Lung Cancer
46%
Patients with Cancer
45%
Phase II Trial
42%
Cisplatin
38%
Gemcitabine
36%
COVID-19
34%
Lung
34%
Resectable Pancreatic Cancer
31%
Phase II Study
30%
Advanced Colorectal Cancer
30%
Oxaliplatin
29%
Randomized Phase III Trial
28%
Overall Survival
25%
Panitumumab
24%
Placebo
24%
Irinotecan
23%
Metastatic Colorectal Cancer (mCRC)
23%
BRAF mutant
23%
Pancreatic Ductal Adenocarcinoma
22%
Pancreatic Cancer
21%
Progression-free Survival
21%
Cancer Patients
21%
Immune Response
20%
Randomized Trial
19%
Fluoropyrimidine
19%
5-fluorouracil (5-FU)
18%
Targeted Therapy
18%
Bevacizumab
18%
Head-and-neck Cancer
18%
Fluorouracil
18%
Programmed Death-ligand 1 (PD-L1)
18%
Combination Chemotherapy
17%
Epirubicin
17%
Coronavirus
16%
Clinical Trials
16%
Next-generation Sequencing
16%
GV1001
16%
Hazard Ratio
15%
COVID-19 Mortality
15%
Esophagogastric Adenocarcinoma
15%
Granulocyte Colony-stimulating Factor (G-CSF)
15%
Cancer Evolution
15%
COVID-19 Disease
14%
Small Cell Lung Cancer
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Malignant Neoplasm
97%
Non Small Cell Lung Cancer
66%
Colorectal Carcinoma
65%
Cisplatin
42%
Placebo
40%
Neoplasm
38%
Overall Survival
35%
Capecitabine
34%
Diseases
32%
Fluorouracil
28%
Progression Free Survival
24%
Irinotecan
24%
Oxaliplatin
24%
Pharmacokinetics
23%
Metastatic Colorectal Cancer
23%
Lung Cancer
22%
Fluoropyrimidine
22%
Phase III Trials
21%
Infection
20%
Gemcitabine
20%
Biological Marker
19%
Pancreas Cancer
19%
Bevacizumab
18%
Immunotherapy
17%
Pemetrexed
17%
SARS Coronavirus
16%
Epidermal Growth Factor Receptor
16%
Cetuximab
14%
Clinical Trial
13%
Panitumumab
13%
Prospective Cohort Study
12%
Erlotinib
11%
Bexarotene
11%
Randomized Controlled Trial
11%
Pembrolizumab
11%
Phase I Trials
11%
Epirubicin
11%
Prevalence
11%
Small Cell Lung Cancer
11%
Docetaxel
11%
Paclitaxel
11%
Disease Exacerbation
10%
Adverse Event
10%
Adavosertib
10%
Disease Free Survival
10%
Thromboembolism
9%
Adenocarcinoma
9%
Comorbidity
9%
Head and Neck Cancer
8%
Medicine and Dentistry
Malignant Neoplasm
78%
Neoplasm
59%
Colorectal Carcinoma
57%
Non Small Cell Lung Cancer
52%
COVID-19
46%
Capecitabine
34%
Cisplatin
30%
Pancreas Cancer
28%
Placebo
27%
Biological Marker
27%
Lung Cancer
26%
Gemcitabine
23%
Diseases
23%
Epidermal Growth Factor Receptor
22%
Infection
22%
Adenocarcinoma
21%
Severe Acute Respiratory Syndrome Coronavirus 2
21%
Personalized Medicine
20%
Overall Survival
20%
Panitumumab
19%
Head and Neck Cancer
18%
Lung
18%
Epirubicin
17%
Targeted Therapy
16%
Metastatic Carcinoma
16%
Oxaliplatin
15%
Arm
15%
Pemetrexed
14%
Fluorouracil
13%
Medicine
13%
Quality of Life
12%
Transcriptome
12%
Pancreas Adenocarcinoma
12%
Coronavirinae
12%
Cancer
11%
Randomized Controlled Trial
11%
Bevacizumab
11%
Prospective Cohort Study
11%
Cancer Surgery
11%
Fibroblast
11%
Immunotherapy
10%
Prevalence
10%
Disease Free Survival
10%
Primary Tumor
9%
Cancer Research
9%
Odds Ratio
9%
Next Generation Sequencing
8%
Adjuvant Chemotherapy
8%
Progression Free Survival
8%
T Cell
8%